These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21703321)

  • 21. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income Countries.
    Harmon TM; Fisher KA; McGlynn MG; Stover J; Warren MJ; Teng Y; Näveke A
    PLoS One; 2016; 11(1):e0146387. PubMed ID: 26731116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials.
    O'Hagan JJ; Hernán MA; Walensky RP; Lipsitch M
    AIDS; 2012 Jan; 26(2):123-6. PubMed ID: 22045345
    [No Abstract]   [Full Text] [Related]  

  • 24. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
    Akapirat S; Karnasuta C; Vasan S; Rerks-Ngarm S; Pitisuttithum P; Madnote S; Savadsuk H; Rittiroongrad S; Puangkaew J; Phogat S; Tartaglia J; Sinangil F; de Souza MS; Excler JL; Kim JH; Robb ML; Michael NL; Ngauy V; O'Connell RJ; Karasavvas N;
    PLoS One; 2018; 13(4):e0196397. PubMed ID: 29702672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.
    Dimitrov D; Kublin JG; Ramsey S; Corey L
    EBioMedicine; 2015 Dec; 2(12):2062-9. PubMed ID: 26844286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand.
    Leelahavarong P; Teerawattananon Y; Werayingyong P; Akaleephan C; Premsri N; Namwat C; Peerapatanapokin W; Tangcharoensathien V
    BMC Public Health; 2011 Jul; 11():534. PubMed ID: 21729309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
    Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
    PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa.
    Bos JM; Postma MJ
    Pharmacoeconomics; 2001; 19(9):937-46. PubMed ID: 11700780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example.
    Andersson KM; Owens DK; Vardas E; Gray GE; McIntyre JA; Paltiel AD
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):78-90. PubMed ID: 17589368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV.
    Fonseca MG; Forsythe S; Menezes A; Vuthoori S; Possas C; Veloso VG; Lucena Fde F; Stover J
    PLoS One; 2010 Jul; 5(7):e11736. PubMed ID: 20668523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand.
    Ono S; Kurotaki T; Nakasone T; Honda M; Boon-Long J; Sawanpanyalert P; Kimura K
    Jpn J Infect Dis; 2006 Jun; 59(3):168-73. PubMed ID: 16785697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness and delivery study for future HIV vaccines.
    Barth-Jones DC; Cheng H; Kang LY; Kenya PR; Odera D; Mosqueira NR; Mendoza W; Portela MC; Brito C; Tangcharoensathien V; Akaleephan C; Supantamart S; Patcharanarumol W; de Macedo Brigido LF; Fonseca MG; Sanchez M; Chang ML; Osmanov S; Avrett S; Esparza J; Griffiths U;
    AIDS; 2005 Sep; 19(13):w1-6. PubMed ID: 16103763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk compensation after HIV-1 vaccination may accelerate viral adaptation and reduce cost-effectiveness: a modeling study.
    Peebles K; Mittler JE; Goodreau SM; Murphy JT; Reid MC; Abernethy N; Gottlieb GS; Barnabas RV; Herbeck JT
    Sci Rep; 2021 Mar; 11(1):6798. PubMed ID: 33762616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential population health outcomes and expenditures of HIV vaccination strategies in the United States.
    Long EF; Brandeau ML; Owens DK
    Vaccine; 2009 Aug; 27(39):5402-10. PubMed ID: 19591796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
    Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
    PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Male circumcision at different ages in Rwanda: a cost-effectiveness study.
    Binagwaho A; Pegurri E; Muita J; Bertozzi S
    PLoS Med; 2010 Jan; 7(1):e1000211. PubMed ID: 20098721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study.
    Shrestha S; Chihota V; White RG; Grant AD; Churchyard GJ; Dowdy DW
    Am J Epidemiol; 2017 Dec; 186(12):1362-1369. PubMed ID: 29253139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.
    Pitisuttithum P; Rerks-Ngarm S; Bussaratid V; Dhitavat J; Maekanantawat W; Pungpak S; Suntharasamai P; Vanijanonta S; Nitayapan S; Kaewkungwal J; Benenson M; Morgan P; O'Connell RJ; Berenberg J; Gurunathan S; Francis DP; Paris R; Chiu J; Stablein D; Michael NL; Excler JL; Robb ML; Kim JH
    PLoS One; 2011; 6(12):e27837. PubMed ID: 22205930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.